The new drug policy is a hotchpotch of measures that do not address the many problems typical to the Indian pharmaceutical industry. Its prescriptions - whether with regard to price control, MAPE or FDI regulations - do not take into cognisance the differentiated nature of the sector in India and may well affect the industry negatively in the long run.
Subscribers please login to access full text of the article.
EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.
Bibtex
Endnote
RIS
Google Scholar
Comments
EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.